Editorial: National Medicines Policy 2.0—what’s changed and what’s next?

IF 3.4 Q2 PHARMACOLOGY & PHARMACY Australian Prescriber Pub Date : 2023-12-12 DOI:10.18773/austprescr.2023.023

Andrew J McLachlan, Parisa Aslani

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

社论：国家药品政策 2.0--有何变化？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Australian Prescriber MEDICINE, GENERAL & INTERNAL-PHARMACOLOGY & PHARMACY

CiteScore

3.80

自引率

7.40%

发文量

审稿时长

>12 weeks

期刊介绍： Australian Prescriber is Australia''s free, national, independent journal of drugs and therapeutics. It is published every two months online. Our purpose is to help health professionals make informed choices when prescribing, including whether to prescribe a drug or not. To do this we provide independent, reliable and accessible information. As well as publishing short didactic reviews, we facilitate debate about complex, controversial or uncertain therapeutic areas. We are part of NPS MedicineWise, an independent, non-profit organisation providing medicines information and resources for health professionals, and stakeholders involved in the quality use of medicines. NPS MedicineWise is funded by the Australian Government Department of Health.

期刊最新文献

Avacopan for antineutrophil cytoplasmic antibody-associated vasculitis. Clascoterone for acne. Fezolinetant for moderate to severe vasomotor symptoms associated with menopause. Immune checkpoint inhibitors and immune-related adverse events. Inhaler device selection for people with asthma or chronic obstructive pulmonary disease.